A DRVVT screen is a specialized blood-clotting test that detects lupus anticoagulant, a type of antibody linked to abnormal blood clotting and pregnancy complications. The test uses a tiny amount of venom from the Russell’s viper snake to activate clotting directly, then measures whether something in the patient’s blood is slowing that process down. If the clotting time is prolonged, it suggests lupus anticoagulant antibodies may be present, and further steps are taken to confirm the finding. Despite its name, this test is not limited to people with lupus and has become one of the most widely recommended first-line assays for identifying a clinically important clotting disorder.
Why Snake Venom Is Involved
The “RVV” in DRVVT stands for Russell’s viper venom. The venom of Russell’s viper, a snake native to South Asia, contains a protein that directly activates factor X, a key player in the chain of reactions that forms a blood clot. Dr. Patrick Russell first identified the venom during work on snake bites in India, and Dr. Robert Macfarlane later adapted it for laboratory use, initially to help control bleeding in hemophilia patients.1PubMed. Russell Viper Venom: A Journey from the Bedside to the Bench and Back to the Bedside That ability to jump straight to factor X, bypassing the earlier steps in the clotting cascade, turns out to be extremely useful for detecting lupus anticoagulant. Lupus anticoagulant antibodies interfere with clotting reactions that depend on phospholipids, the fatty molecules that serve as a surface for clotting factors to assemble on. By triggering factor X directly and using a deliberately small amount of phospholipid in the test mixture (the “D” stands for “dilute”), the DRVVT is designed to be highly sensitive to even modest interference from these antibodies.
How the Antibodies Interfere with the Test
Lupus anticoagulant antibodies don’t attack clotting factors themselves. Instead, they bind to proteins that sit on phospholipid surfaces, particularly a protein called beta-2 glycoprotein I. When these antibodies latch onto those surface proteins, they disrupt the normal assembly of clotting complexes, slowing down the reaction. The DRVVT deliberately uses a low concentration of phospholipid to make the test more sensitive to this disruption. Research has shown that a certain amount of phospholipid in the DRVVT system is needed to express the lupus anticoagulant activity of anti-beta-2 glycoprotein I antibodies, and that the DRVVT is more sensitive than several other clotting-based tests for detecting this particular type of antibody.2Thrombosis and Haemostasis. dRVVT Is more Sensitive than KCT or TTI for Detecting Lupus Anticoagulant Activity of Anti-β2-glycoprotein I Autoantibodies That sensitivity to anti-beta-2 glycoprotein I is clinically significant because these antibodies are among those most strongly associated with blood clots.
The Three-Step Process
A DRVVT is not just a single measurement. The International Society on Thrombosis and Haemostasis recommends a three-step procedure: screen, mix, and confirm.3Journal of Laboratory Physicians. Comparison of screen-confirm versus screen-mix-confirm algorithms for lupus anticoagulant detection by dilute Russell’s viper venom time Each step answers a different question.
- Screen: The patient’s plasma is mixed with diluted Russell’s viper venom and a small amount of phospholipid, then the clotting time is measured. If the time is normal, lupus anticoagulant is unlikely and testing usually stops here.
- Mix: If the screen is prolonged, the patient’s plasma is mixed 1:1 with normal pooled plasma and the test is repeated. This step helps distinguish lupus anticoagulant from a simple clotting factor deficiency. If the patient is just missing a clotting factor, adding normal plasma (which contains all the factors) should correct the prolonged time. If lupus anticoagulant antibodies are present, the clotting time stays prolonged even after the mix, because the antibodies continue to interfere.
- Confirm: The test is repeated using a much higher concentration of phospholipid. If the problem was lupus anticoagulant antibodies binding to phospholipid surfaces, flooding the system with excess phospholipid overwhelms their interference and the clotting time normalizes. That normalization is the confirmation.
The logic is elegant: the screen catches the prolongation, the mix rules out factor deficiency, and the confirm proves the prolongation was phospholipid-dependent. All three steps pointing in the right direction gives you a positive lupus anticoagulant result.
How Results Are Expressed
Raw clotting times in seconds are not directly comparable from one laboratory to another because different reagents, instruments, and techniques shift the numbers. To standardize results, labs convert the raw times into ratios by dividing the patient’s clotting time by the clotting time of a normal reference plasma. Each center establishes its own normal reference range using plasma from healthy local donors. A large multicenter study found that using a cutoff of the mean plus two standard deviations for the DRVVT ratio, combined with a percentage-correction approach for the confirmatory step, achieved a sensitivity of about 81% and a specificity of about 94% for correctly identifying lupus anticoagulant.4British Journal of Haematology. The importance of locally derived reference ranges and standardized calculation of dilute Russell’s viper venom time results in screening for lupus anticoagulant One center in southern India, for example, derived cutoff values of about 45.5 seconds for the dRVVT screen and a normalized ratio cutoff around 1.16.5PubMed Central. Assessment of Normative Range and Deriving Cut-Off Values for Lupus Anticoagulant Testing: An Experience from a Tertiary Care Center in Southern India Those specific numbers vary between institutions, which is the whole point of local reference ranges: what counts as “abnormally prolonged” depends on your lab’s setup.
Because different commercial DRVVT kits exist, and they don’t all produce identical numbers, some labs further normalize ratios using the mean of their reference interval. A comparison of six different DRVVT kits found measurable differences between them when testing the same samples, underscoring the importance of each lab validating its own cutoffs rather than borrowing numbers from another facility.6PubMed. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits
The Paradox in the Name
The word “anticoagulant” in lupus anticoagulant is one of the most confusing things in clinical medicine. In the test tube, these antibodies slow clotting, making the blood appear to be anti-coagulated. But in the body, they do the opposite: they increase the risk of inappropriate blood clots.7PubMed. The Lupus Anticoagulant Paradox This in-vitro-versus-in-vivo contradiction has puzzled researchers for decades. One or more clotting tests come back prolonged, seemingly pointing to a bleeding tendency, while clinically the patient faces excessive thrombosis.8PubMed. The enigmas of the lupus anticoagulant: mechanisms, diagnosis, and management
The name “lupus” is equally misleading. These antibodies were first discovered in patients with systemic lupus erythematosus, but they are found in many people who do not have lupus. They can appear temporarily after infections or with certain medications, or they can persist as part of antiphospholipid syndrome, an autoimmune condition that can exist on its own.
Why the DRVVT Screen Matters Clinically
The reason labs bother with this test is that lupus anticoagulant is one of the strongest laboratory predictors of blood clots and pregnancy complications in antiphospholipid syndrome. The DRVVT in particular has been shown in several studies to be specific for detecting lupus anticoagulant in patients at high risk for thrombosis and more sensitive for that purpose than some alternative clotting-based assays.9American Society for Clinical Laboratory Science. Laboratory Diagnosis of the Lupus Anticoagulant – Section: Dilute Russell Viper Venom Time
In a study of patients with COVID-19 admitted to intensive care, those who tested positive for lupus anticoagulant by DRVVT had roughly two-and-a-half times the odds of developing a blood clot, and in patients at or below the median age of 64, that risk jumped to about four-and-a-half times higher.10PubMed Central. Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units: A retrospective cohort study The predictive value may be even stronger when a patient tests positive on both the DRVVT and a second assay called the silica clotting time. Dual positivity was associated with significantly higher rates of persistent lupus anticoagulant and higher co-occurrence of other antiphospholipid antibodies.11PubMed. Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction
Pregnancy Complications and DRVVT-Based Lupus Anticoagulant
Lupus anticoagulant is not only linked to venous and arterial blood clots. It is also a recognized risk factor for pregnancy loss, preeclampsia, and other obstetric complications. In a study of pregnancies in women with systemic lupus erythematosus, those who had a positive lupus anticoagulant during the first trimester experienced pregnancy loss at a rate of about 38%, compared with roughly 9% in those without it.12Lupus Science & Medicine. Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss
More recent work has specifically evaluated DRVVT-based lupus anticoagulant measurement as a predictor of adverse pregnancy outcomes. In a study of over 1,200 pregnant women, including 165 with a history of at least one obstetric feature of antiphospholipid syndrome, the DRVVT-based lupus anticoagulant showed strong predictive value for early-onset preeclampsia, with an area under the curve of approximately 0.8 across multiple statistical models.13PubMed Central. Prognostic Value of Lupus Anticoagulant and Anti–β2 Glycoprotein I Antibody in Adverse Pregnancy Outcomes That’s a meaningful level of predictive accuracy for a single lab test. For pregnant women with suspected antiphospholipid syndrome, the DRVVT screen is often one of the first tests ordered.
How Blood Thinners Muddy the Results
Here is where things get frustrating for both patients and clinicians. Lupus anticoagulant testing uses clot-based assays, which means any drug that affects clotting will also affect the test. The patients who most need the test, those being investigated for abnormal clotting, are often already on blood thinners. This creates a catch-22.
Direct oral anticoagulants, commonly known as DOACs, are among the worst offenders. Rivaroxaban, dabigatran, edoxaban, and apixaban all prolong DRVVT results in a concentration-dependent way, and the DRVVT is more affected than other lupus anticoagulant assays.14Journal of Thrombosis and Haemostasis. Evaluation of DOAC-Stop to overcome direct oral anticoagulant interference in lupus anticoagulant testing False-positive lupus anticoagulant results, where the test says antibodies are present but they’re actually not, start appearing at surprisingly low drug concentrations. For rivaroxaban, false-positive conclusions have been seen starting from concentrations as low as 35 nanograms per milliliter, and for dabigatran, from about 50 nanograms per milliliter.14Journal of Thrombosis and Haemostasis. Evaluation of DOAC-Stop to overcome direct oral anticoagulant interference in lupus anticoagulant testing Another study found that up to about 71% of dabigatran-spiked samples showed abnormal DRVVT ratios, and rivaroxaban affected both spiked and actual patient samples.15Thrombosis Research. Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants Even at expected trough levels (the lowest drug concentration between doses), the false-positive rate has been called “unacceptably high.”16PubMed. Lupus-anticoagulant testing at NOAC trough levels
Vitamin K antagonists like warfarin also interfere, though in a somewhat different way. Because warfarin reduces the production of several clotting factors, it can prolong clotting times and produce either false-positive or false-negative lupus anticoagulant results depending on the specific circumstances.
Stripping Out Drug Interference
Laboratories have developed workarounds for DOAC interference. One approach uses activated charcoal products that physically adsorb the drug out of the plasma sample before the test is run. A product called DOAC Remove reduced DOAC concentrations below clinically significant levels and corrected the interference with DRVVT assays in the majority of tested patient samples.17Thrombosis Research. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants Another study specifically examined rivaroxaban interference and found that DOAC Stop, a similar charcoal-based product, neutralized the false-positive lupus anticoagulant result, bringing the DRVVT screen-to-confirm ratio back to normal.18Thrombosis Research. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa These tools are not universally available in every hospital lab, but their use is growing as DOACs become more commonly prescribed.
The simplest approach, when clinically safe, is to stop the blood thinner temporarily before testing. DOACs clear the body faster than warfarin, so a washout period of a few days can be sufficient. But stopping anticoagulation in a patient with a recent blood clot carries its own risks, which is why the charcoal-based removal methods are valuable for patients who cannot safely stop their medication.
How DRVVT Compares to Other Lupus Anticoagulant Tests
The DRVVT is not the only game in town. Other clotting-based assays used for lupus anticoagulant detection include aPTT-based methods (using a dilute or lupus-sensitive aPTT reagent) and the silica clotting time. Guidelines generally recommend using two different assays based on different principles, with the DRVVT as one of them, to maximize the chance of catching lupus anticoagulant.
The different assays don’t always agree. One study comparing the silica clotting time to both DRVVT and aPTT in patients meeting clinical criteria for antiphospholipid syndrome found that the silica clotting time had higher sensitivity for identifying lupus anticoagulant (about 53%) compared with the DRVVT and aPTT (both around 31%), though the DRVVT had excellent specificity at nearly 99%.19PubMed Central. Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome The trade-off between sensitivity and specificity is a familiar one in lab testing: the DRVVT is less likely to call something positive that isn’t, but it may miss some true positives that other assays catch. Using two assays together compensates for the blind spots of each individual test.
The Algorithm Problem
Even with the same DRVVT kit and the same plasma samples, two laboratories can reach different conclusions about whether lupus anticoagulant is present. That sounds alarming, but it comes down to how the three-step results are interpreted. Different professional guidelines recommend slightly different algorithms for combining the screen, mix, and confirm results into a final yes-or-no answer. A study that applied different published algorithms to the same dataset found that switching from one guideline’s algorithm to another changed roughly a third of DRVVT interpretations from positive to negative.20PubMed Central. Application of different lupus anticoagulant diagnostic algorithms to the same assay data leads to interpretive discrepancies in some samples The mixing step is where most of the disagreement lives: some algorithms require the mix to stay clearly prolonged, while others use different cutoff thresholds or weight the mix result differently against the screen and confirm steps.
This variability means that a borderline result at one institution might be called positive and negative at another. For patients, the practical implication is that a single borderline DRVVT result should not be treated as a definitive diagnosis. Repeat testing after at least 12 weeks, as recommended by current guidelines, helps confirm whether the finding is persistent and clinically meaningful rather than a one-off laboratory artifact.
When a Positive DRVVT Screen Does Not Mean Antiphospholipid Syndrome
A positive DRVVT screen can appear in situations that have nothing to do with antiphospholipid syndrome. Transient lupus anticoagulant is common after viral infections, especially in children, and typically resolves within weeks to months without any clotting complications. It has also been reported during acute illness: the COVID-19 pandemic generated a wave of transiently positive lupus anticoagulant results in critically ill patients, many of whom likely did not have true antiphospholipid syndrome.
Certain medications, particularly some antibiotics and psychiatric drugs, can trigger transient lupus anticoagulant as well. This is one reason the diagnostic criteria for antiphospholipid syndrome require that lupus anticoagulant be confirmed on at least two occasions separated by at least 12 weeks. A single positive result, even a strongly positive one, does not by itself establish the diagnosis. The persistence requirement filters out the many transient causes and focuses attention on the patients who have a durable, clinically relevant antibody.
For anyone whose doctor has ordered this test, the key takeaway is that the DRVVT screen is the first step in a careful, multi-stage process. A prolonged screen triggers further investigation, not a diagnosis. Even a fully confirmed positive result needs to be repeated weeks later and interpreted alongside the clinical picture: the patient’s history of blood clots, pregnancy complications, or other features of antiphospholipid syndrome. The test’s strength lies in that structured approach, each step narrowing down the possibilities until the laboratory and clinical evidence converge.